Adragos acquires Baccinex: the advisors
Pestalozzi and Kellerhals Carrard both advised Adragos Pharma, a pharmaceutical contract development and manufacturing organization (CDMO) headquartered in Munich, Germany, in the acquisition of Baccinex, an aseptic fill-finish manufacturing based in Courroux, Jura, Switzerland. With this acquisition, Adragos Pharma strengthens its sterile manufacturing capabilities with specialized expertise in aseptic fill-finish and lyophilization.
The addition of Baccinex marks Adragos’ 6th global manufacturing site. The expansion fits a strategy dedicated to enhancing clinical and commercial pharmaceutical production.
The Pestalozzi team
Pestalozzi advised Adragos Pharma on Swiss law aspects of the transaction with a multi-disciplinary team. The team was comprised of Christian Leuenberger (partner – Corporate / M&A, pictured right), Raphael Widmer (associate – Corporate / M&A, pictured left), Fabienne Schaub (junior associate – Corporate / M&A), Andrew Galantay (junior associate – Corporate / M&A), Michael Lips (partner – Real Estate), Melanie von Rickenbach (associate – Real Estate), Sarah Drukarch (partner – Life Sciences), Carola Winzeler (associate – Life Sciences), Jonas Sigrist (partner – Tax), Christian Roos (partner – Employment), Seraina Würgler (associate – Employment).
Kellerhal Carrard’s team
Kellerhals Carrard advised Adragos Pharma on all legal aspects of the transaction. The team was led by Nicolas Mosimann (partner-M&A, pictured left) and included Marco Sibold (partner-Tax), Kevin MacCabe (senior associate-M&A), and Sebastian Müller (associate-M&A).
